IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10562854 B1

PDFFull Text
Date of Patent:
Feb. 18, 2020

Filed:

Feb. 20, 2018

Prolyl hydroxylase inhibitors

Applicant:

Aerpio Therapeutics, Inc., Cincinnati, OH (US);

Inventors:

Joseph H. Gardner, Cincinnati, OH (US);

Robert Shalwitz, Bexley, OH (US);

Shengde Wu, Mason, OH (US);

Assignee:

AERPIO THERAPEUTICS, INC., Cincinnati, OH (US);

Attorney:

Seed IP Law Group LLP

Primary Examiner:

Alexander R Pagano

Assistant Examiner:

Ebenezer O Sackey

Int. Cl.
CPC ...
C07D 211/96 (2006.01); C07D 211/86 (2006.01); C07D 491/113 (2006.01); C07D 417/06 (2006.01); C07D 401/14 (2006.01); C07D 401/06 (2006.01); C07D 213/69 (2006.01); C07D 213/02 (2006.01); A61K 45/06 (2006.01); A61K 31/444 (2006.01); A61K 31/4427 (2006.01); A61K 31/55 (2006.01); A61K 31/4439 (2006.01); A61K 31/4545 (2006.01); A61K 31/496 (2006.01); A61K 31/501 (2006.01); A61K 31/5377 (2006.01); A61K 31/541 (2006.01); A61K 31/4412 (2006.01); A61K 31/44 (2006.01);
U.S. Cl.
CPC ...
C07D 211/96 (2013.01); A61K 31/44 (2013.01); A61K 31/444 (2013.01); A61K 31/4412 (2013.01); A61K 31/4427 (2013.01); A61K 31/4439 (2013.01); A61K 31/4545 (2013.01); A61K 31/496 (2013.01); A61K 31/501 (2013.01); A61K 31/5377 (2013.01); A61K 31/541 (2013.01); A61K 31/55 (2013.01); A61K 45/06 (2013.01); C07D 211/86 (2013.01); C07D 213/02 (2013.01); C07D 213/69 (2013.01); C07D 401/06 (2013.01); C07D 401/14 (2013.01); C07D 417/06 (2013.01); C07D 491/113 (2013.01); Y02A 50/401 (2018.01); Y02A 50/465 (2018.01); Y02A 50/47 (2018.01); Y02A 50/471 (2018.01); Y02A 50/473 (2018.01); Y02A 50/475 (2018.01); Y02A 50/478 (2018.01); Y02A 50/481 (2018.01);
Abstract

Disclosed herein are prolyl hydroxylase inhibitors that can stabilize hypoxia inducible factor-1 alpha (HIF-1α), as well as hypoxia inducible factor-2 (HIF-2). Also disclosed herein are pharmaceutical compositions comprising one or more of the disclosed compounds. Yet further disclosed are methods for stimulating the cellular immune response in a mammal such as increasing phagocytosis, for example, prolonging the life of phagocytes, inter alia, kerotyiocytes, neutrophils. As such the disclosed compounds provide methods for treating diseases that relate to the body's immune response.

Find Patent Forward Citations

Loading…